Spero Therapeutics, Inc. (SPRO) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Spero Therapeutics, Inc. (SPRO) Bundle
Designed for accuracy, our Spero Therapeutics, Inc. (SPRO) DCF Calculator enables you to assess the valuation of Spero Therapeutics with real-world financial data and the complete flexibility to modify all essential parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.7 | 9.3 | 18.3 | 48.6 | 96.7 | 191.4 | 378.8 | 749.6 | 1,483.4 | 2,935.5 |
| Revenue Growth, % | 0 | 96.75 | 95.67 | 166.1 | 99.13 | 97.89 | 97.89 | 97.89 | 97.89 | 97.89 |
| EBITDA | -62.5 | -76.9 | -87.2 | -42.3 | 25.8 | -138.0 | -273.0 | -540.3 | -1,069.1 | -2,115.6 |
| EBITDA, % | -1317.29 | -824.59 | -477.49 | -87 | 26.64 | -72.07 | -72.07 | -72.07 | -72.07 | -72.07 |
| Depreciation | 1.2 | 1.3 | 1.1 | 1.5 | .4 | 18.6 | 36.8 | 72.8 | 144.0 | 284.9 |
| Depreciation, % | 24.42 | 14.43 | 6.12 | 3.18 | 0.37939 | 9.71 | 9.71 | 9.71 | 9.71 | 9.71 |
| EBIT | -63.6 | -78.3 | -88.3 | -43.8 | 25.4 | -139.3 | -275.7 | -545.6 | -1,079.7 | -2,136.6 |
| EBIT, % | -1341.71 | -839.01 | -483.61 | -90.18 | 26.26 | -72.78 | -72.78 | -72.78 | -72.78 | -72.78 |
| Total Cash | 82.0 | 126.9 | 146.4 | 109.1 | 76.3 | 183.4 | 362.8 | 718.0 | 1,420.8 | 2,811.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 8.5 | 6.2 | 2.6 | 1.1 | 50.7 | 90.1 | 178.3 | 352.8 | 698.1 | 1,381.4 |
| Account Receivables, % | 180.22 | 66.2 | 14.47 | 2.23 | 52.41 | 47.06 | 47.06 | 47.06 | 47.06 | 47.06 |
| Inventories | -13.4 | -12.2 | .0 | -4.5 | .0 | -80.1 | -158.5 | -313.6 | -620.6 | -1,228.1 |
| Inventories, % | -281.93 | -131.18 | 0 | -9.19 | 0 | -41.84 | -41.84 | -41.84 | -41.84 | -41.84 |
| Accounts Payable | 4.1 | 1.2 | 1.1 | .6 | 1.4 | 41.6 | 82.2 | 162.8 | 322.1 | 637.3 |
| Accounts Payable, % | 87.45 | 12.38 | 6.03 | 1.27 | 1.42 | 21.71 | 21.71 | 21.71 | 21.71 | 21.71 |
| Capital Expenditure | -.3 | -.2 | .0 | .0 | .0 | -3.2 | -6.3 | -12.5 | -24.6 | -48.8 |
| Capital Expenditure, % | -6.62 | -1.68 | 0.21363 | 0 | 0 | -1.66 | -1.66 | -1.66 | -1.66 | -1.66 |
| Tax Rate, % | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 | 10.23 |
| EBITAT | -62.8 | -77.5 | -89.8 | -45.3 | 22.8 | -135.9 | -268.9 | -532.0 | -1,052.8 | -2,083.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -53.0 | -78.1 | -97.4 | -38.2 | -30.1 | -39.6 | -207.5 | -410.6 | -812.5 | -1,607.9 |
| WACC, % | 7.15 | 7.15 | 7.15 | 7.15 | 7.11 | 7.14 | 7.14 | 7.14 | 7.14 | 7.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,306.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,640 | |||||||||
| Terminal Value | -31,885 | |||||||||
| Present Terminal Value | -22,582 | |||||||||
| Enterprise Value | -24,889 | |||||||||
| Net Debt | -71 | |||||||||
| Equity Value | -24,818 | |||||||||
| Diluted Shares Outstanding, MM | 53 | |||||||||
| Equity Value Per Share | -468.36 |
What You Will Get
- Real Spero Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Spero Therapeutics, Inc. (SPRO).
- Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates specific to Spero Therapeutics.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Spero Therapeutics, Inc.'s (SPRO) fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections tailored for Spero Therapeutics.
- Time-Saving and Accurate: Eliminate the need to build models from scratch while ensuring precision and flexibility for Spero Therapeutics, Inc. (SPRO).
Key Features
- Comprehensive SPRO Data: Pre-filled with Spero Therapeutics’ historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Develop multiple forecasting scenarios to evaluate different valuation outcomes.
- User-Friendly Design: Intuitive, structured, and tailored for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Spero Therapeutics, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for investment decisions regarding Spero Therapeutics, Inc. (SPRO).
Why Choose This Calculator for Spero Therapeutics, Inc. (SPRO)?
- Accurate Data: Real-time Spero Therapeutics financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech industry.
- User-Friendly: Easy-to-navigate layout and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions regarding Spero Therapeutics, Inc. (SPRO) stock transactions.
- Financial Analysts: Enhance valuation methodologies with accessible financial models tailored for Spero Therapeutics, Inc. (SPRO).
- Consultants: Provide clients with precise and timely valuation analysis for Spero Therapeutics, Inc. (SPRO).
- Business Owners: Learn how biopharmaceutical companies like Spero Therapeutics, Inc. (SPRO) are valued to inform your own business strategies.
- Finance Students: Acquire practical valuation skills using real-world examples from Spero Therapeutics, Inc. (SPRO).
What the Template Contains
- Pre-Filled Data: Includes Spero Therapeutics’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC using custom inputs.
- Key Financial Ratios: Analyze Spero Therapeutics’ profitability, efficiency, and leverage.
- Customizable Inputs: Easily edit revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing key valuation results.